🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Extensively Hydrolyzed formula

    United Therapeutics Europe Ltd

    Cow Milk Allergy

    phase 3 other completed

    1 trial

  2. FF/UMEC/VI

    Grace Therapeutics

    Asthma

    phase 3 small molecule active

    1 trial

  3. FKB238 (bevacizumab)

    Centus Biotherapeutics Europe Limited

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  4. FLORTAUCIPIR (18F), FLORTAUCIPIR (18F), FLORBETAPIR (18F), FLORBETAPIR (18F)

    The George Institute

    Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia

    phase 3 small molecule active

    1 trial

  5. FLUCONAZOLE , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMOXICILLIN , METRONIDAZOLE , CIPROFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CLINDAMYCIN , DOXYCYCLINE , LINEZOLID , SODIUM CHLORIDE SOLUTION 0.9%

    The George Institute

    Patients with hip or knee infections

    phase 3 small molecule active

    1 trial

  6. FLUOROURACIL, BEVACIZUMAB, FOLINIC ACID, OXALIPLATIN, ivonescimab

    Summit Therapeutics

    Metastatic colorectal cancer

    phase 3 small molecule active

    1 trial

  7. FLUOROURACIL, Tecentriq 1 200 mg concentrate for solution for infusion, CALCIUM FOLINATE PENTAHYDRATE, OXALIPLATIN

    The George Institute

    stage III colon adenocarcinoma with deficient MMR

    phase 3 small molecule active

    1 trial

  8. FMX-101, 4% minocycline foam

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    2 trials

  9. FMX101

    Cutia Therapeutics (Shanghai) Co., Ltd

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  10. FMX101

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  11. FMX103 1.5%

    VYNE Therapeutics

    Papulopustular Rosacea

    phase 3 small molecule completed

    1 trial

  12. FMX103 minocycline foam 1.5%

    VYNE Therapeutics

    Facial Papulopustular Rosacea

    phase 3 small molecule completed

    2 trials

  13. FUROSEMIDE, FUROSEMIDE, FUROSEMIDE, HYDROCHLOROTHIAZIDE

    The George Institute

    Acute Heart Failure

    phase 3 small molecule active

    1 trial

  14. FX006

    Pacira Ireland Limited

    Osteoarthritis of the Knee

    phase 3 small molecule completed

    2 trials

  15. FX006 32 mg

    Pacira Ireland Limited

    Osteoarthritis of the Knee

    phase 3 small molecule completed

    4 trials

  16. Farletuzumab

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  17. Fasedienol Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder (SAD)

    phase 3 small molecule active

    1 trial

  18. Fasedienol Nasal Spray

    Vistagen Therapeutics

    Social Anxiety Disorder

    phase 3 small molecule active

    1 trial

  19. Fasinumab

    Regeneron UK Limited

    Osteoarthritis of the Knee or Hip

    phase 3 small molecule completed

    1 trial

  20. Femara 2.5 mg film-coated tablets, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Anastrozole 1mg film-coated tablets, Docetaxel Pfizer 10 mg/mL concentrate for solution for infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Exemestane 25 mg Film-coated Tablets, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Abraxane 5 mg/ml powder for dispersion for infusion.

    Ningbo Cancer Hospital

    low-grade serous carcinoma of the ovary or peritoneum

    phase 3 small molecule active

    1 trial

  21. Ficerafusp alfa

    Bicara Therapeutics

    Metastatic Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  22. Filgotinib

    Lakefront Biotherapeutics NV

    Ulcerative Colitis

    phase 3 small molecule completed

    2 trials

  23. Filgotinib

    Lakefront Biotherapeutics NV

    Crohn's Disease

    phase 3 small molecule completed

    2 trials

  24. Filgotinib

    Lakefront Biotherapeutics NV

    Psoriatic Arthritis

    phase 3 small molecule terminated

    4 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources